Immunotherapy and chemo for pleural mesothelioma that returned
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new immunotherapy drug (cadonilimab) when combined with chemotherapy for people whose pleural mesothelioma has come back or not responded to earlier treatment. The goal is to see if adding this drug can help shrink tumors or slow the cancer better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of mesothelioma that started in the lining of the lungs (called pleural mesothelioma) and is advanced or has spread.
- You must have already received one type of chemotherapy (platinum-based) and it either didn't work or the cancer came back.
- You can have had at most 2 prior treatments for your cancer.
- You must be able to care for yourself and be up and about (performance status 0 or 1).
- Your liver, kidneys, and blood counts must be good enough to safely get the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
Hear when a new Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.